Monitor FDA review progress and any updates on modular review acceptance. The RMAT designation allows for rolling and priority review, which could accelerate timeline. Approval would open a new market in LVAD-related complications, but clinical data adequacy remains key.
Price Chart
Executive Summary
Mesoblast received a BLA filing number from the FDA and requested a modular review for rexlemestrocel-L in end-stage heart failure patients with LVADs. The drug has Orphan Drug and RMAT designations, and the company highlighted recent FDA guidance on regulatory flexibility for orphan rare diseases. This is a positive regulatory milestone but does not guarantee approval.
Key Facts
- Received BLA filing number from FDA for rexlemestrocel-L in end-stage heart failure with LVADs
- Requested modular review of the BLA
- Rexlemestrocel-L has Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations
- FDA recently issued draft guidance on flexibility for demonstrating substantial evidence of effectiveness for orphan rare diseases
Financial Impact
No financial figures disclosed; regulatory milestone with potential future revenue if approved
Risk Factors
- FDA may not accept modular review or may require additional clinical data
- Competition from other therapies for LVAD-related gastrointestinal bleeding
- Commercial adoption depends on pricing and reimbursement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000062 |
| Exhibit: exhibit991lvadblasubmiss.htm | 0001345099-26-000062 |
| Document: 0001345099-26-000062-index-headers.html | 0001345099-26-000062 |
| Document: 0001345099-26-000062-index.html | 0001345099-26-000062 |
| Document: 0001345099-26-000062.txt | 0001345099-26-000062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.06 (−22.66%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.06 (−22.66%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.06 (−15.50%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.06 (−17.39%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.06 (−3.37%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.06 (−16.01%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.06 (−16.01%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.06 (−8.94%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.06 (−8.94%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.06 (−0.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access